Cited by 940Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.

CTLA-4: new insights into its biological function and use in tumor immunotherapy

Egen, Jackson G., Kuhns, Michael S., Allison, James P.·2002·Nature Immunology

Open this paper in CoChat — free account

Abstract

The discovery of multiple costimulatory cell surface molecules that influence the course of T cell activation has increased our appreciation of the complexity of the T cell response. It remains clear, however, that CD28 and cytotoxic T lymphocyte antigen 4 (CTLA-4) are the critical costimulatory receptors that determine the early outcome of stimulation through the T cell antigen receptor (TCR). Details of how the T cell integrates TCR stimulation with the costimulatory signals of CD28 and the inhibitory signals of CTLA-4 remain to be established, but unique features of the cell biology of CTLA-4 provide important insights into its function. We summarize here recent findings that suggest a previously unrecognized role for CTLA-4 in the regulation of T cell responses. We also describe preclinical and clinical results that indicate manipulation of CTLA-4 has considerable promise as a strategy for the immunotherapy of cancer.

Integrity signals

Registry

Crossref · 10.1038/ni0702-611

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citation
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
Dranoff, G., Jaffee, E. M., Lazenby, A., Golumbek, P. T., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. M., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,820
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
Self-citation
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation
Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206
B7/CD28 Costimulation Is Essential for the Homeostasis of the CD4+CD25+ Immunoregulatory T Cells that Control Autoimmune Diabetes
Salomon, B. L., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A. H., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,058
The B7–CD28 superfamily
Sharpe, A. H., & Freeman, G. J. (2002) · Nature reviews. Immunology · doi:10.1038/nri727 · Cited by 1,759

Show all 93 references

Sorted by citations

Items 701–800 of 940

Strong-Arming Immune Regulation: Suppressing Regulatory T-Cell Function To Treat Cancers
Knutson, K. L. (2006) · Future Oncology · doi:10.2217/14796694.2.3.379 · Cited by 7
Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy
Page, D., Yuan, J., Redmond, D., Wen, Y., Durack, J., Emerson, R., Solomon, S. B., Dong, Z., Wong, P., Comstock, C., et al. (2019) · immuneACCESS · doi:10.21417/dbp2016cir · Cited by 7
Self-citation
CTLA4 expression profiles and their association with clinical outcomes of breast cancer: a systemic review
Jin, T. Y., Park, K. S., Nam, S. E., Lim, S. H., Kim, J. H., Noh, W. C., Yoo, Y. B., Park, W. S., & Yun, I. J. (2024) · Annals of Surgical Treatment and Research · doi:10.4174/astr.2024.106.5.263 · Cited by 6
Dynamic Tuning of T Cell Receptor Specificity by Co-Receptors and Costimulation
van den Berg, H. A., & Sewell, A. K. (2011) · Springer eBooks · doi:10.1007/978-1-4419-7725-0_3 · Cited by 6
Dose-Dependent Effect of Tumor Mutation Burden on Cancer Prognosis Following Immune Checkpoint Blockade: Causal Implications
Zheng, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.853300 · Cited by 6
Cytotoxic T-lymphocyte-associated antigen-4 polymorphisms and susceptibility to cervical cancer: A meta-analysis
Qiu, H., Tang, W., Yin, P., CHENG, F., & Wang, L. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1721 · Cited by 6
Effect of combined OX40Ig and CTLA4Ig gene local transfer on allograft rejection and the underlying mechanisms
Zhang, J., Miao, Q., Yang, Y., Xiao, B., Liu, B., Cao, J., Hao, X.-Y., Wang, S., & Guo, S. (2012) · Journal of Surgical Research · doi:10.1016/j.jss.2012.05.034 · Cited by 6
Checkpoint Inhibition for Colorectal Cancer: Progress and Possibilities
Paul, B. A., O’Neil, B. H., & McRee, A. J. (2016) · Immunotherapy · doi:10.2217/imt-2016-0013 · Cited by 6
Development of novel avenues to overcome challenges facing CAR T cells
Kim, S., & Moon, E. K. (2017) · Translational research · doi:10.1016/j.trsl.2017.05.009 · Cited by 6
Immunotherapy for prostate cancer
Fong, L. H., & Small, E. J. (2007) · Current Prostate Reports · doi:10.1007/s11918-007-0001-z · Cited by 6
T Cell Activation and Function: Role of Signal Strength
Ahmed, A., & Nandi, D. (2011) · Springer eBooks · doi:10.1007/978-1-4419-7725-0_4 · Cited by 6
Cumulative dermatologic toxicity with ipilimumab and vemurafenib responsive to corticosteroids
Ludlow, S. P., & Pasikhova, Y. (2013) · Melanoma Research · doi:10.1097/cmr.0000000000000018 · Cited by 6
Targeted Therapy in Oncology
Mishra, B. K., & Parikh, P. M. (2006) · Medical Journal Armed Forces India · doi:10.1016/s0377-1237(06)80063-8 · Cited by 6
Blockade of CTLA-4 (CD152) enhances the murine antibody response to pneumococcal capsular polysaccharides
Boudewijns, M., Jeurissen, A., Wuyts, M., Moens, L., Boon, L., van Neerven, R. J. J., Kasran, A., Overbergh, L., Lenaerts, C., Waer, M., et al. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.1004562 · Cited by 6
Implications of altered O-glycosylation in tumour immune evasion
Itano, N. (2019) · The Journal of Biochemistry · doi:10.1093/jb/mvz003 · Cited by 6
DNA Methylation-Based Panel Predicts Survival of Patients With Clear Cell Renal Cell Carcinoma and Its Correlations With Genomic Metrics and Tumor Immune Cell Infiltration
Liu, X., Ju, L., Chen, C., Liu, T., Li, S., & Wang, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.572628 · Cited by 6
Moving forward with immunotherapy: the rationale for anti-CTLA-4 therapy in melanoma
Margolin, K. A. (2008) · Community Oncology · doi:10.1016/s1548-5315(11)70470-3 · Cited by 6
Cytotoxic T lymphocyte-associated antigen-4 +49A>G polymorphism and the risk of non-small cell lung cancer in a Chinese population.
Liu, H.-N., Su, J., Zhou, S., Liu, L., & Qie, P. (2015) · PubMed Central · Cited by 6
Immunotherapy and Cancer Therapeutics: Why Partner?
Emens, L. A., & Jaffee, E. M. (2007) · Elsevier eBooks · doi:10.1016/b978-012372551-6/50076-6 · Cited by 6
Assembling atomic resolution views of the immunological synapse
Wang, J., & Eck, M. J. (2003) · Current Opinion in Immunology · doi:10.1016/s0952-7915(03)00055-4 · Cited by 6
Immune Checkpoint Inhibitors
Kaliński, P., & Basse, P. H. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54948-6.00001-9 · Cited by 6
Efficacy and safety of abatacept for interstitial lung disease associated with antisynthetase syndrome: a case series
Xia, N., Hong, S.-M., Zhang, X., Shao, C., Yan, N., Ding, H., & Guo, Q. (2022) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/53puzu · Cited by 5
Fighting with the Enemys Weapons? The Role of Costimulatory Molecules in HIV
Keersmaecker, B. D., Thielemans, K., & Aerts, J. L. (2011) · Current Molecular Medicine · doi:10.2174/156652411795243397 · Cited by 5
Melanoma Vaccines and Modulation of the Immune System in the Clinical Setting: Building from New Realities
Rowdo, F. P. M., Lacreu, M. L., & Mordoh, J. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00103 · Cited by 5
The Role of the Intestinal Microbiome in the Immunotherapy of Colon Cancer
Хакимова, Г. Г., Tryakin, A. A., Заботина, Т. Н., Цуканов, А. С., Алиев, В. А., & Гуторов, С. Л. (2019) · Malignant tumours · doi:10.18027/2224-5057-2019-9-2-5-11 · Cited by 5
Structural Insights into N-heterocyclic Moieties as an Anticancer Agent against Hepatocellular Carcinoma: An Exhaustive Perspective
Chourasiya, N. K., Fatima, F., Mishra, M., Kori, S. K., Das, R., Kashaw, V., Iyer, A. K., & Kashaw, S. K. (2023) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557523666230508160924 · Cited by 5
The prognostic significance of immune checkpoint receptor expression in patients with lymphoma: Association with disease status and clinical outcomes
Shokrgozar, N., Dehghani, M., Golmoghaddam, H., Moghadam, M., Rezaei, N., Moayed, V., & Arandi, N. (2022) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13730 · Cited by 5
Emerging drugs for chronic lymphocytic leukaemia
Yee, K. W. L., & O'Brien, S. M. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.1.167 · Cited by 5
The Immune Synapse as a Novel Target for Therapy
Graca, L. (2007) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8296-4 · Cited by 5
Functional analysis of CTLA4 promoter variant and its possible implication in colorectal cancer immunotherapy
Angulo-Aguado, M., Orjuela-Amarillo, S., Mora-Jácome, J. F., Córdoba, L. P., Gallego-Ortiz, A., Gaviria-Sabogal, C. C., Contreras, N., Figueroa, C., Ortega‐Recalde, O., Morel, A., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1160368 · Cited by 4
FGL2 as a predictive biomarker for prognosis and immunotherapy in bladder cancer
Huang, Z., Wang, Z., Xu, C., Yan, Y., Cao, X., Zhang, F., & Shen, B. Q. (2024) · International Journal of Medical Sciences · doi:10.7150/ijms.91874 · Cited by 4
A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers
Nahas, G. R., Walker, N. D., Bryan, M., & Rameshwar, P. (2015) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s29425 · Cited by 4
Tumor immune evasion mediated by IDO
Munn, D. H. (2006) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2006.05.009 · Cited by 4
Fighting Fire with Fire in Cancer
Berger, T., Saunders, M. E., & Mak, T. W. (2015) · Springer eBooks · doi:10.1007/978-4-431-55651-0_3 · Cited by 4
Association of cytotoxic T‐lymphocyte associated protein 4 gene polymorphisms with the risk and prognosis of oesophageal cancer in a high‐incidence region from northern China
Wang, L., Li, Y., Wang, N., Huang, X., Cao, S., & Zhou, R. (2019) · International Journal of Immunogenetics · doi:10.1111/iji.12470 · Cited by 4
The role of immune checkpoint inhibitors in triple-negative breast cancer: recent developments and future perspectives
Papadimitriou, M., Liakouli, Z., & PAPADIMITRIOU, C. A. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.138 · Cited by 4
Demystifying Skin Color and “Race”
Cheng, K. C. (2008) · Springer eBooks · doi:10.1007/978-0-387-79098-5_1 · Cited by 4
Immune Co-signaling to Treat Cancer
Callahan, M. K., Wolchok, J. D., Allison, J. P., & Sharma, P. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4732-0_8 · Cited by 4
Self-citation
Effect of Cytotoxic T-Lymphocyte Antigen-4 on the Efficacy of the Fatty Acid-Binding Protein Vaccine Against Schistosoma japonicum
Tang, C., Pan, Q., Xie, Y., Xiong, Y., Zhang, R., & Huang, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01022 · Cited by 4
Evaluation of Laboratory Application of Camelid Sera Containing Heavy-Chain Polyclonal Antibody Against Recombinant Cytotoxic T-Lymphocyte-Associated Protein-4
Sotoudeh, N., Noormohammadi, Z., Habibi‐Anbouhi, M., Kazemi‐Lomedasht, F., & Behdani, M. (2019) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2019.0031 · Cited by 4
Adaptive Immunity
Birdsall, H. H. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00005-9 · Cited by 4
Characterization of CD25‐Positive T Cells During Syngeneic Pregnancy: Production of Stimulatory Class II MHC Molecules
Kyvelidou, C., Chatzi, K. E., Semitekolou, M., Papathanassiou, X., Vassiliadis, S., & Athanassakis, I. (2009) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2009.02342.x · Cited by 4
Therapeutic vaccines for non-Hodgkin B-cell lymphoma
Briones, J. (2008) · Clinical & Translational Oncology · doi:10.1007/s12094-008-0249-4 · Cited by 4
El potencial de la inmunomodulación con anticuerpos monoclonales anti-CD137 (4-1BB) para terapia de enfermedades malignas e infecciones virales crónicas
Alfaro, C., Murillo, O., Tirapu, I., Azpilicueta, A., Huarte, E., Arina, A., Arribillaga, L., Perez‐Gracia, J. L., Bendandi, M., Prìeto, J., et al. (2006) · Anales del Sistema Sanitario de Navarra · doi:10.4321/s1137-66272006000100007 · Cited by 4
Two different forms of human CTLA-4 proteins following peripheral T cell activation
Chun, T., Choi, H.-J., & Chung, Y.-H. (2004) · Immunology Letters · doi:10.1016/j.imlet.2003.12.004 · Cited by 4
Immune intervention with monoclonal antibodies targeting CD152 (CTLA-4) for autoimmune and malignant diseases.
Chin, L., Chu, C., Chen, H., Wang, D.-W., & Liao, S. (2008) · PubMed · Cited by 4
Génétique des maladies systémiques
Dieudé, P. (2007) · Revue du Rhumatisme · doi:10.1016/j.rhum.2007.07.002 · Cited by 4
Building a better model of cancer.
Marusyk, A., & DeGregori, J. V. (2006) · Cell Division · doi:10.1186/1747-1028-1-24 · Cited by 4
CTLA4 Single-Nucleotide Polymorphisms Influence the Risk of HSV and VZV Infection in Kidney Transplant Recipients: A Prospective Cohort Study
Redondo, N., Rodríguez‐Góncer, I., Ruiz‐Merlo, T., López‐Medrano, F., González, E., Polanco, N., Hernández-Vicente, A., Juan, R. S., Belmonte, A. A., Aguado, J. M., et al. (2025) · Transplant International · doi:10.3389/ti.2025.14648 · Cited by 3
Targeting LRBA triggers CTLA4 degradation and antitumor immunity for cancer immunotherapy
Ge, X., Yu, L., Zhang, L., Jia, L., Meng, M., He, J., Bu, F., Song, Y., Sun, G., Lv, S.-M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67365-5 · Cited by 3
Immunotherapy and postoperative bone defect repair strategies based on osteosarcoma tumor microenvironment characteristics: balancing antitumor effects and promotion of bone regeneration
Guo, Q., Ran, C., Wang, Z., Zhang, X., Yao, Y., Chen, X. Y., Zhang, Y., Yang, J., You, Y., & Dw, Z. (2026) · Regenerative Biomaterials · doi:10.1093/rb/rbag031 · Cited by 3
Bifurcations of a cancer immunotherapy model explaining the transient delayed response and various other responses
Zhang, W., Zheng, C. Y., & Kim, P. (2024) · Communications in Nonlinear Science and Numerical Simulation · doi:10.1016/j.cnsns.2024.108047 · Cited by 3
Checkpoint agonists — immunoregulatory role and its implications in the treatment of psoriasis and psoriatic arthritis
Baroz, A. R., Lee, D. K., Maverakis, N., Raychaudhuri, S. P., & Raychaudhuri, S. P. (2025) · Current Opinion in Immunology · doi:10.1016/j.coi.2025.102641 · Cited by 3
Antibodies to Stimulate Host Immunity
Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394296-8.00019-1 · Cited by 3
Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab
Mouri, A., Watanabe, S., Tokito, T., Nagai, Y., Saida, Y., Imai, H., Yamaguchi, O., Kobayashi, K., Kaira, K., & Kagamu, H. (2024) · Cancers · doi:10.3390/cancers16071409 · Cited by 3
What’s New in Dermatopathology: Inflammatory Dermatoses
Penn, L. A., Rothman, L. R., Sutton, A. M., Brinster, N. K., & Vidal, C. I. (2018) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000210 · Cited by 3
50 Jahre Systemtherapie des Harnblasenkarzinoms
Retz, M. M., Amsberg, G. V., Horn, T. D., Gschwend, J. E., & Maisch, P. (2019) · Aktuelle Urologie · doi:10.1055/a-0945-8340 · Cited by 3
The Potential Role of Inhibitory Receptors in the Treatment of Psoriasis.
Shah, N., Sandigursky, S., & Mor, A. (2017) · PubMed · Cited by 3
Comprehensive analysis of a new immune-related prognostic signature for esophageal cancer and its correlation with infiltrating immune cells and target genes
Zhang, P., Liu, X., Cheng, Z., Wu, K., & Zhao, S. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-4756 · Cited by 3
Gene Signatures with Therapeutic Value: Emerging Perspective for Personalized Immunotherapy in Renal Cancer
Ahluwalia, P. K., Mondal, A. K., Sahajpal, N., Rojiani, M. V., & Kolhe, R. B. (2021) · Immunotherapy · doi:10.2217/imt-2021-0187 · Cited by 3
The Role of the Key Differentially Mutated Gene FGFR3 in the Immune Microenvironment of Bladder Cancer
Jun, J., Zhan, Y., & Li, J. (2022) · Journal of Immunology Research · doi:10.1155/2022/7952706 · Cited by 3
Comprehensive bioinformatic analysis constructs a CXCL model for predicting survival and immunotherapy effectiveness in ovarian cancer
Li, S., Zou, D., & Liu, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1127557 · Cited by 3
Prostate Cancer
Nelson, W. G., Carter, H. B., DeWeese, T. L., & Eisenberger, M. A. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50092-0 · Cited by 3
Cutting into innate immunity
Winoto, A. (2004) · Nature Immunology · doi:10.1038/ni0604-563 · Cited by 3
Manipulating T regulatory cells in cancer immunotherapy
Rüter, J., Barnett, B. G., Kryczek, I., Brumlik, M. J., Daniel, B. J., Coukos, G., Zou, W., & Curiel, T. J. (2006) · Expert Review of Dermatology · doi:10.1586/17469872.1.4.589 · Cited by 3
Overexpression of a mutant CTLA4 inhibits T-cell activation and homeostasis-driven expansion
Mao, Y. V., Brigham, D., & Chen, D. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2004.04.011 · Cited by 3
Engineering strategies and binding mechanisms of therapeutic anti–PD-1 antibodies approved by regulatory agencies globally
Almagro, J. C., Gómez-Castellano, K., Licona‐Limón, I., Carballo‐Uicab, G., Ramírez-Villedas, F., Montes-Luna, A., González‐González, E., Godínez-Palma, S., Barrera-Saldaña, H. A., & Pérez‐Tapia, S. M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1834585 · Cited by 2
Anti-CTLA-4 Ab
Tokudome, T. (2016) · Springer eBooks · doi:10.1007/978-4-431-55031-0_18 · Cited by 2
Molecular biology of the novel anticancer medications: a focus on kinases inhibitors, biologics and CAR T-cell therapy
Abdo, E.-L., Ajib, I., Mounzer, J. E., Husseini, M., Kalaoun, G., Matta, T.-M., Mosleh, R., Nasr, F., Richani, N., Khalil, A., et al. (2025) · Inflammation Research · doi:10.1007/s00011-025-02008-5 · Cited by 2
Immunotherapy as an Optimal Manner in Cancer Treatment (Review Article)
Shabgah, A. G., Navashenaq, J. G., Mahboobi, M., & Sedighian, H. (2014) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/1502 · Cited by 2
Immune reaction by cytoreductive prostatectomy.
Lee, G. T., Srivastava, A., Kwon, Y. S., & Kim, I. Y. (2019) · PubMed Central · Cited by 2
Immune Landscape and Role of Immunotherapy in Treatment of HPV-Associated Head and Neck Squamous Cell Carcinoma (HNSCC)
Turbeville, H. R., Toni, T., & Allen, C. T. (2022) · Current Otorhinolaryngology Reports · doi:10.1007/s40136-021-00384-0 · Cited by 2
Application of Computational Techniques in Antibody Fc-Fused Molecule Design for Therapeutics
Ng, C. L., Lim, T. S., & Choong, Y. S. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00885-x · Cited by 2
Updates on the Importance of CD200:CD200R Checkpoint Blockade in Solid Tumors and B cell Malignancies
Gorczynski, R. M. (2023) · Journal of Oncology Research and Therapy · doi:10.29011/2574-710x.10185 · Cited by 2
The Relationship Between CTLA-4 (-318 C/T) Polymorphism and Urothelial Cancer Carcinogenesis in Japanese Patients
Damayanti, P., Hlaing, S. T. M., Aung, K. Z., Tsukino, H., Hinoura, T., & Kuroda, Y. (2023) · Cureus · doi:10.7759/cureus.48068 · Cited by 2
Immune checkpoints in B-cell Lymphoma: Still an Unmet challenge from Basic research to clinical practice
Li, S., Pan, Y., Ye, R., Wang, Y., & Li, L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113717 · Cited by 2
Biological Microniches Characterizing Pathological Lesions
Meraz, I. M., Segura-Ibarra, V., Leonard, F., Gonzalez, J., Ally, S., Godin, B., & Serda, R. E. (2013) · Frontiers of nanoscience · doi:10.1016/b978-0-08-098338-7.00006-6 · Cited by 2
The Role of Cytotoxic T-Lymphocyte Associated Antigen 4 (CTLA4) +49A/G and Tumor Necrosis Factor Alpha (TNF-.ALPHA.) -308G/A Polymorphism in the Development of Celiac Disease in Jordanian Patients
El-Akawi, Z. J., & Mansour, A. S. (2010) · Eisei kagaku · doi:10.1248/jhs.56.41 · Cited by 2
Monoclonal Antibodies in Pediatric Acute Lymphoblastic Leukemia
Chen, C. I.-U. (2017) · Springer eBooks · doi:10.1007/978-3-319-39708-5_9 · Cited by 2
Analysis for Science Librarians of the 2018 Nobel Prize in Physiology or Medicine: The Life and Work of James P. Allison and Tasuku Honjo
Gilman, N. (2019) · Science & Technology Libraries · doi:10.1080/0194262x.2018.1558165 · Cited by 2
Administration of anti‐CTLA‐4 monoclonal antibody augments protective immunity induced by Schistosoma japonicum glutathione‐S‐transferase
Tang, C., Pan, Q., Dai, W., Li-dong, H., Zhou, H., & Wang, L. (2019) · Parasite Immunology · doi:10.1111/pim.12657 · Cited by 2
Antibodies
Birdsall, H. H. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00006-0 · Cited by 2
Immunotherapy for Advanced Melanoma
Roman, R.-A. (2011) · Clinical journal of oncology nursing · doi:10.1188/11.cjon.e58-e65 · Cited by 2
Cytotoxic T-Lymphocyte-Associated Antigen 4 Gene Polymorphisms in Japanese Children with Infection-Associated Hemophagocytic Lymphohistiocytosis
Yoshiyama, M., Kounami, S., Nakayama, K., Okutani, T., Aoyagi, N., & Yoshikawa, N. (2010) · Acta Haematologica · doi:10.1159/000295572 · Cited by 2
Nanotechnology-Based Immunotherapeutic Strategies for the Treatment of Cancer
Sharma, R. K., Mody, N., & Vyas, S. P. (2017) · Springer eBooks · doi:10.1007/978-981-10-3647-7_3 · Cited by 2
Common strategies for effective immunotherapy of gastroesophageal cancers using immune checkpoint inhibitors
Ma, S., & Chen, F. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154110 · Cited by 2
Recent advances in therapeutic strategies for SLE
Stichweh, D., Pascual, V., & Banchereau, J. (2006) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2006.02.003 · Cited by 2
Blockade of the Activation of T Cells Around β-Cell by the Targeted CTLA-4 Ig at the Surface of β-Cell
Qu, W., Li, L., Han, C., Li, M., Wang, J., Yin, C., Zhang, J., & Jiang, Z. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-0282-0 · Cited by 1
CTLA-4 and targeted immunotherapy—a key link in the systemic influence of periodontitis: a mini review
Thanigaimalai, A., Ravindran, D. M., Balaji, S., Bhuvaneswari, B., & SriSanjhanaa, C. (2025) · Frontiers in Dental Medicine · doi:10.3389/fdmed.2025.1700665 · Cited by 1
CTLA-4: a promising immunosuppressive immune checkpoint in prostate cancer therapy
Younis, N. K., Al-Hussainy, A. F., Jyothi, S. R., Nayak, P. P., Janney, J. B., Singh, G., Polatova, D., Sameer, H. N., Salih, R. M., & Adil, M. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-025-04213-4 · Cited by 1
Is platinum the new gold? Re-evaluating platinum's enduring role and future potential in the era of novel ovarian cancer therapies
Roa, A. P., Muthuramalingam, R. P. K., Lopez‐Sanchez, A., Deng, L., Gibson, D., Bertrand, H. C., Adriani, G., Ang, W. H., & Pastorin, G. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114996 · Cited by 1
Efficacy of PD-1/PD-L1 plus CTLA-4 inhibitors in advanced/metastatic NSCLC: a meta-analysis based on RCTs
Dai, T., Chen, Y., Dai, X., Chen, Y., Pan, X., Chen, J., & Liu, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1833277 · Cited by 1
Mechanisms of Immune Cell Dysregulation in Pancreatic Ductal Adenocarcinoma
Ahmady, F., Luwor, R. B., & Kannourakis, G. (2026) · Biology · doi:10.3390/biology15181599 · Cited by 1
Co-Receptors in the Positive and Negative Regulation of T-Cell Immunity
Schneider, H., & Rudd, C. E. (2008) · Springer eBooks · doi:10.1007/978-4-431-73884-8_8 · Cited by 1
Direct sequencing for comprehensive screening of LDLR genetic polymorphisms among five ethnic populations
Kim, J., Cheong, H. S., Kim, L. H., Shin, H. J., Na, H. S., Chung, M. W., & Shin, H. D. (2014) · Genes & Genomics · doi:10.1007/s13258-014-0244-3 · Cited by 1
Identifying population differences in genes that affect body mass index
Williams, S. M. (2013) · Genome Medicine · doi:10.1186/gm506 · Cited by 1
Harnessing the immune system to cure cancer
Huang, Y. (2014) · Translational Cancer Research · doi:10.21037/2802 · Cited by 1
Cancer-Specific Vaccines
Pardoll, D. M. (2008) · Elsevier eBooks · doi:10.1016/b978-141603703-3.10054-8 · Cited by 1
Biomarkers for Immune Checkpoint Inhibitors
Sharif, P. M., Keshavarz‐Fathi, M., & Rezaei, N. (2020) · Springer eBooks · doi:10.1007/978-3-030-50287-4_25 · Cited by 1
Intrinsic and acquired cancer immunotherapy resistance
Saleh, R., Nair, V. S., Toor, S. M., & Elkord, E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823397-9.00014-4 · Cited by 2

Authors: Egen, J. G., Kuhns, M. S., & Allison, J. P.
Affiliations: Howard Hughes Medical Institute (US)
Corresponding author: Allison, James P.
ORCID: Egen, Jackson G.
Kuhns, Michael S.
Allison, James P.
Venue: Nature Immunology
Publisher: Springer Science and Business Media LLC
Published: 2002-07
Volume: 3
Issue: 7
Pages: 611-618
ISSN: 1529-2908 (ISSN-L)
1529-2916
DOI: 10.1038/ni0702-611
OpenAlex: W2140460887
Cited by: 940
References: 93
Citations by year: 2026: 10 · 2025: 15 · 2024: 30 · 2023: 34 · 2022: 45 · 2021: 50 · 2020: 43 · 2019: 33 · 2018: 27 · 2017: 36 · 2016: 28 · 2015: 32 · 2014: 31 · 2013: 38 · 2012: 25
FWCI: 5.88
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Immunology (publishedVersion)
PubMed (publishedVersion)
Funders: Howard Hughes Medical Institute
National Institutes of Health
National Cancer Institute (CA40041, R01CA057986, CA57986)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CTLA-4, costimulatory receptors, CD28, T cell activation, T cell receptor signaling, T cell regulation, cancer immunotherapy, CTLA-4 blockade, immune checkpoint blockade
MeSH terms: Abatacept, Animals, Antigens, Differentiation, Cell Division, Colonic Neoplasms, Disease Models, Animal, Fibrosarcoma, Gene Expression Regulation, Humans, Immunotherapy, Lymphocyte Activation, Neoplasms, T-Lymphocytes, Antigens, CD, Immunoconjugates, Mice, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CTLA-4: new insights into its biological function and use in tumor immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks